CSIMarket
 


Bicycle Therapeutics Plc  (BCYC)
Other Ticker:  
 
 

BCYC's Capital Expenditures Growth by Quarter and Year

Bicycle Therapeutics Plc's Capital Expenditures results by quarter and year




BCYC Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 0.05 1.45 1.07 0.48
III Quarter September 0.50 2.98 0.17 0.10
II Quarter June 0.28 9.80 0.17 0.30
I Quarter March 2.10 4.76 0.62 0.32
FY   2.93 18.99 2.03 1.20



BCYC Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Bicycle Therapeutics Plc reported drop in Capital Expenditures in the fourth quarter 2023 by -96.48% to $ 0.05 millions, from the same quarter in 2022.
The fall in the fourth quarter 2023 Bicycle Therapeutics Plc's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 287.53%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 17 other companies have achieved higher Capital Expenditures growth. While Bicycle Therapeutics Plc' s Capital Expenditures meltdown of -96.48% ranks overall at the positon no. 397 in the fourth quarter 2023.




BCYC Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -96.48 % 35.51 % 122.92 % 23.08 %
III Quarter September -83.22 % 1652.94 % 70 % -91.38 %
II Quarter June -97.14 % 5664.71 % -43.33 % -
I Quarter March -55.88 % 667.74 % 93.75 % -
FY   -84.57 % 835.47 % 69.17 % -22.58 %

Financial Statements
Bicycle Therapeutics Plc's fourth quarter 2023 Capital Expenditures $ 0.05 millions BCYC's Income Statement
Bicycle Therapeutics Plc's fourth quarter 2022 Capital Expenditures $ 1.45 millions Quarterly BCYC's Income Statement
New: More BCYC's historic Capital Expenditures Growth >>


BCYC Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -89.8 % -51.34 % 529.41 % 380 %
III Quarter September 78.57 % -69.59 % 0 % -66.67 %
II Quarter June -86.67 % 105.88 % -72.58 % -6.25 %
I Quarter March 44.83 % 344.86 % 29.17 % -17.95 %
FY (Year on Year)   -84.57 % 835.47 % 69.17 % -22.58 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #18
Healthcare Sector #44
Overall #397

Capital Expenditures Y/Y Growth Statistics
High Average Low
1185.83 % 287.53 % -84.57 %
(Sep 30 2022)   (Dec 31 2023)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #18
Healthcare Sector #44
Overall #397
Capital Expenditures Y/Y Growth Statistics
High Average Low
1185.83 % 287.53 % -84.57 %
(Sep 30 2022)   (Dec 31 2023)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Bicycle Therapeutics Plc's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
531.36 % 59.83 % -89.84 %
(Dec 31 2021)  


BCYC's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Bicycle Therapeutics Plc realized fall in Capital Expenditures from the previous quarter by -89.8% to $ 0.05 millions, from $ 0.50 millions achived in the previous quarter.

If you look into present downturn at the IV. Quarter, you suppose to presume, that usually IV. Quarter performance appear to be softer in contrast to the quarter before

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Bicycle Therapeutics Plc's Capital Expenditures growth quarter on quarter, overall rank is 930.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #109
Overall #930
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #109
Overall #930
Capital Expenditures Q/Q Growth Statistics
High Average Low
531.36 % 59.83 % -89.84 %
(Dec 31 2021)  


BCYC's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Bicycle Therapeutics Plc realized fall in Capital Expenditures from the previous quarter by -89.8% to $ 0.05 millions, from $ 0.50 millions achived in the previous quarter.

It's not important issue, as Capital Expenditures generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Bicycle Therapeutics Plc's Capital Expenditures growth quarter on quarter, overall rank is 930.


Bicycle Therapeutics Plc's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 2.93 $ 4.33 $ 6.81 $ 16.33 $ 18.99
Y / Y Capital Expenditures Growth (TTM) -84.57 % -76.75 % -56.89 % 164.97 % 835.32 %
Year on Year Capital Expenditures Growth Overall Ranking # 3 # 12 # 3 # 20 # 434
Seqeuential Capital Expenditures Change (TTM) -32.29 % -36.46 % -58.31 % -13.99 % 2.05 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 397 # 1020 # 39 # 36 # 702




Cumulative Capital Expenditures growth Comment
Bicycle Therapeutics Plc's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -84.57% year on year, at Dec 31 2023 compare to the -76.75% decrease at Sep 30 2023. If the Bicycle Therapeutics Plc's fiscal year would end at Dec 31 2023, annual Capital Expenditures would be $3 millions.

Bicycle Therapeutics Plc achieved highest trailing twelve month year on year Capital Expenditures growth. While Total ranking has impoved so far to 3, from total ranking in previous quarter at 12.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1185.83 %
287.53 %
-84.57 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 18
Healthcare Sector # 0
Overall # 3

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1185.83 %
287.53 %
-84.57 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 44
S&P 500 # 397
Cumulative Capital Expenditures growth Comment
Bicycle Therapeutics Plc's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -84.57% year on year, at Dec 31 2023 compare to the -76.75% decrease at Sep 30 2023. If the Bicycle Therapeutics Plc's fiscal year would end at Dec 31 2023, annual Capital Expenditures would be $3 millions.

Bicycle Therapeutics Plc achieved highest trailing twelve month year on year Capital Expenditures growth. While Total ranking has impoved so far to 3, from total ranking in previous quarter at 12.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1185.83 %
287.53 %
-84.57 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 18
Healthcare Sector # 0
Overall # 3

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1185.83 %
287.53 %
-84.57 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 44
S&P 500 # 397




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
BCYC's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for BCYC's Competitors
Capital Expenditures Growth for Bicycle Therapeutics Plc's Suppliers
Capital Expenditures Growth for BCYC's Customers

You may also want to know
BCYC's Annual Growth Rates BCYC's Profitability Ratios BCYC's Asset Turnover Ratio BCYC's Dividend Growth
BCYC's Roe BCYC's Valuation Ratios BCYC's Financial Strength Ratios BCYC's Dividend Payout Ratio
BCYC's Roa BCYC's Inventory Turnover Ratio BCYC's Growth Rates BCYC's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Stereotaxis Inc -0.81%$ -0.813 millions
Icon Plc-1.03%$ -1.033 millions
Alpine Immune Sciences Inc -1.72%$ -1.724 millions
Argenx se-2.99%$ -2.987 millions
Abbvie inc -3.76%$ -3.756 millions
Vanda Pharmaceuticals Inc -3.80%$ -3.802 millions
Warby Parker Inc -4.52%$ -4.516 millions
Bristol myers Squibb Company-4.62%$ -4.624 millions
Baxter International Inc -5.00%$ -5.000 millions
Progyny Inc -5.55%$ -5.548 millions
Koru Medical Systems Inc-6.92%$ -6.916 millions
Ufp Technologies Inc -7.02%$ -7.018 millions
Bio rad Laboratories Inc -7.27%$ -7.272 millions
Endo International Plc-8.13%$ -8.130 millions
Eterna Therapeutics Inc -9.52%$ -9.524 millions
Sotera Health Company-9.63%$ -9.633 millions
Hutchmed china Limited-11.05%$ -11.052 millions
Petvivo Holdings Inc-11.46%$ -11.461 millions
Novartis Ag-11.52%$ -11.519 millions
Charles River Laboratories International inc -12.02%$ -12.020 millions
Surgery Partners Inc -12.78%$ -12.775 millions
Xbiotech Inc -12.88%$ -12.879 millions
Conmed Corporation-14.46%$ -14.464 millions
Msa Safety Incorporated-14.60%$ -14.601 millions
Teva Pharmaceutical Industries Limited-16.20%$ -16.197 millions
Genedx Holdings Corp -16.28%$ -16.279 millions
Dexcom Inc -17.32%$ -17.323 millions
Davita Inc -17.74%$ -17.739 millions
Voyager Therapeutics Inc -19.08%$ -19.078 millions
Natera inc -19.40%$ -19.405 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com